Targeted drug doubles progression free survival in Hodgkin lymphoma
Thursday, March 19, 2015 - 10:00
in Health & Medicine
A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo -- 43 months vs 24 months.